The bone marrow microenvironment as a mediator of chemoresistance in acute lymphoblastic leukemia

Abstract

Acute lymphoblastic leukemia (ALL) is a malignancy of immature lymphoid cells that arises due to clonal expansion of cells that undergo developmental arrest and acquisition of pathogenic mutations. With the introduction of intensive multi-agent chemotherapeutic regimens, survival rates for ALL have improved dramatically over the past several decades, though survival rates for adult ALL continue to lag behind those of pediatric ALL. Resistance to chemotherapy remains a significant obstacle in the treatment of ALL, and chemoresistance due to molecular alterations within ALL cells have been described. In addition to these cell-intrinsic factors, the bone marrow microenvironment has more recently been appreciated as a cell-extrinsic mediator of chemoresistance, and it is now known that stromal cells within the bone marrow microenvironment, through direct cell-cell interactions and through the release of lymphoid-acting soluble factors, contribute to ALL pathogenesis and chemoresistance. This review discusses mechanisms of chemoresistance mediated by factors within the bone marrow microenvironment and highlights novel therapeutic strategies that have been investigated to overcome chemoresistance in this context.

Keywords

Acute lymphoblastic leukemia / chemotherapy / chemoresistance / bone marrow microenvironment

References

[1] Pui CH,Evans WE.Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?.Blood2012;120:1165-74 PMCID:PMC3418713

[2] Ronson A,Rowe JM.Treatment of relapsed/refractory acute lymphoblastic leukemia in adults..Curr Oncol Rep2016;18:39

[3] Liu YF,Zhang WN,Li BS.Genomic profiling of adult and pediatric B-cell acute lymphoblastic leukemia..EBioMedicine2016;8:173-83 PMCID:PMC4919728

[4] Liu Y,Shao Y,Wang Z.The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia..Nat Genet2017;49:1211-8 PMCID:PMC5535770

[5] De Keersmaecker K,Li N,Patchett S.Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia..Nat Genet2013;45:186-90 PMCID:PMC5547913

[6] Lugthart S,den Boer ML,Holleman A.Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia..Cancer Cell2005;7:375-86

[7] Holleman A,den Boer ML,Veerman AJP.Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment..N Engl J Med2004;351:533-42

[8] Stam RW,Schneider P,Hagelstein J.Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia..Blood2010;115:1018-25

[9] Piovan E,Tosello V,Ambesi-Impiombato A.Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia..Cancer Cell2013;24:766-76 PMCID:PMC3878658

[10] Li Y,Canté-Barrett K,Vroegindeweij EM.IL-7 receptor mutations and steroid resistance in pediatric T cell acute lymphoblastic leukemia: a genome sequencing study..PLoS Med2016;13:e1002200 PMCID:PMC5172551

[11] Bakker E,Mutti L,Krstic-Demonacos M.The role of microenvironment and immunity in drug response in leukemia..Biochim Biophys Acta2016;1863:414-26

[12] Konopleva M,Zeng Z.Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches..Drug Resist Updat2009;12:103-13 PMCID:PMC3640296

[13] Tavor S.Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia?.Semin Cancer Biol2010;20:178-85

[14] Konopleva MY.Leukemia stem cells and microenvironment: biology and therapeutic targeting..Journal of clinical oncology2011;29:591-9 PMCID:PMC4874213

[15] Manabe A,Behm FG,Campana D.Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia..Blood1992;79:2370-7

[16] Manabe A,Coustan-Smith E,Behm FG.Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells..Blood1994;83:758-66

[17] Takada Y,Simon S.The integrins..Genome Biol2007;8:215 PMCID:PMC1929136

[18] Hsieh YT,Geng H,Huantes S.Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy..Blood2013;121:1814-8 PMCID:PMC3591800

[19] Shalapour S,Kirschner-Schwabe R,Eckert C.High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at first relapse..Haematologica2011;96:1627-35 PMCID:PMC3208680

[20] Shishido S,Kim YM.Role of integrin alpha4 in drug resistance of leukemia..Front Oncol2014;4:99 PMCID:PMC4033044

[21] Bradstock K,Bianchi A.Analysis of the mechanism of adhesion of precursor-B acute lymphoblastic leukemia cells to bone marrow fibroblasts..Blood1993;82:3437-44

[22] Papayannopoulou T,Nakamoto B,Wolf NS.The VLA4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen..Proc Natl Acad Sci USA1995;92:9647-51 PMCID:PMC40859

[23] Craddock CF,Elices M.The role of CS1 moiety of fibronectin in VLA mediated haemopoietic progenitor trafficking..Br J Haematol1997;97:15-21

[24] Mudry RE,York T,Gibson LF.Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy..Blood2000;96:1926-32

[25] Sarkar S,de Beaumont R.The role of Aktand RAFTK in beta1 integrin mediated survival of precursor B-acute lymphoblastic leukemia cells..Leuk Lymphoma2002;43:1663-71

[26] Astier AL,Svoboda M,Munoz O.Temporal gene expression profile of human precursor B leukemia cells induced by adhesion receptor: identification of pathways regulating B-cell survival..Blood2003;101:1118-27

[27] Jacamo R,Wang Z,Zhang M.Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance..Blood2014;123:2691-702 PMCID:PMC3999754

[28] Arcangeli A,Becchetti A.Targeting ion channels in leukemias: a new challenge for treatment..Curr Med Chem2012;19:683-96

[29] Pillozzi S,De Lorenzo E,Cilia E.Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers..Blood2011;117:902-14

[30] Kapp TG,Sobahi TR.Integrin modulators: a patent review..Expert Opin Ther Pat2013;23:1273-95

[31] Hsieh YT,Shishido SN,Pham J.Effects of the small-molecule inhibitor of integrin α4, TBC3486, on pre-BALL cells..Leukemia2014;28:2101-4 PMCID:PMC4190402

[32] Fagerholm SC,Stefanidakis M,Gahmberg CG.Alpha-chain phosphorylation of the human leukocyte CD11b/CD18 (Mac-1) integrin is pivotal for integrin activation to bind ICAMs and leukocyte extravasation..Blood2006;108:3379-86

[33] Rhein P,Basso G,Dworzak MN.CD11b is a therapy resistance- and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemia..Blood2010;115:3763-71

[34] Naci D,Chetoui N,Sigaux F.α2β1 integrin promotes chemoresistance against doxorubicin in cancer cells through extracellular signal-regulated kinase (ERK)..J Biol Chem2012;287:17065-76 PMCID:PMC3366820

[35] Angst BD,Magee AI.The cadherin superfamily: diversity in form and function..J Cell Sci2001;114:629-41

[36] Heuberger J.Interplay of cadherin-mediated cell adhesion and canonical Wnt signaling..Cold Spring Harb Perspect Biol2010;2:a002915 PMCID:PMC2828280

[37] Chae WJ.Canonical and non-canonical wnt signaling in immune cells..Trends Immunol2018;39:830-47

[38] Neumann M,Schlee C,Heesch S.FAT1 expression and mutations in adult acute lymphoblastic leukemia..Blood Cancer J2014;4:e224 PMCID:PMC4080215

[39] Morris LGT,Gong Y,Walsh LA.Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation..Nat Genet2013;45:253-61 PMCID:PMC3729040

[40] Yang Y,Sun B,Kim S-B.Wnt pathway contributes to the protection by bone marrow stromal cells of acute lymphoblastic leukemia cells and is a potential therapeutic target..Cancer Lett2013;333:9-17 PMCID:PMC3880833

[41] Hogan LE,Yang J,Wong N.Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies..Blood2011;118:5218-26 PMCID:PMC3217405

[42] Dandekar S,Pais F,Jones C.Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia..Br J Haematol2014;167:87-99 PMCID:PMC4207443

[43] de Bock CE,Molloy TJ,Johnstone D.The Fat1 cadherin is overexpressed and an independent prognostic factor for survival in paired diagnosis-relapse samples of precursor B-cell acute lymphoblastic leukemia..Leukemia2012;26:918-26

[44] de Bock CE,Baidya K,Boyd AW.T-cell acute lymphoblastic leukemias express a unique truncated FAT1 isoform that cooperates with NOTCH1 in leukemia development..Haematologica2019;104:e204-e207 PMCID:PMC6518915

[45] Yau T,Ng CCW.Lectins with potential for anti-cancer therapy..Mol Basel Switz2015;20:3791-810 PMCID:PMC6272365

[46] Thijssen VL,Caers J.Galectin expression in cancer diagnosis and prognosis: a systematic review..Biochim Biophys Acta2015;1855:235-47

[47] Nabi IR,Dennis JW.The galectin lattice at a glance..J Cell Sci2015;128:2213-9

[48] Yamamoto-Sugitani M,Ashihara E,Kobayashi T.Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia..Proc Natl Acad Sci USA2011;108:17468-73 PMCID:PMC3198366

[49] Fei F,Lim M,von Itzstein M.Galectin-3 in pre-B acute lymphoblastic leukemia..Leukemia2013;27:2385-8 PMCID:PMC3926504

[50] Fei F,Tarighat SS,Paz H.B-cell precursor acute lymphoblastic leukemia and stromal cells communicate through Galectin-3..Oncotarget2015;6:11378-94 PMCID:PMC4484463

[51] Hu K,Lou L,Hu Y.Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via Wnt/β-catenin signaling pathway..J Hematol OncolJ Hematol Oncol2015;8:1 PMCID:PMC4332970

[52] Ruvolo PP,Benton CB,Burks JK.Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells..Biochim Biophys Acta2016;1863:562-71 PMCID:PMC4775369

[53] Clark MC,Hsu DK,de Vos S.Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death..Blood2012;120:4635-44 PMCID:PMC3512238

[54] Streetly MJ,Joel S,Gribben JG.GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death..Blood2010;115:3939-48 PMCID:PMC5292593

[55] Chauhan D,Podar K,Neri P.A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells..Cancer Res2005;65:8350-8

[56] Nwabo Kamdje AH.Notch signaling in acute lymphoblastic leukemia: any role for stromal microenvironment?.Blood2011;118:6506-14

[57] Li X.Notch signaling in T-Cell development and T-ALL..ISRN Hematol2011;2011:921706 PMCID:PMC3200084

[58] Schmitt TM.Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro..Immunity2002;17:749-56

[59] Siebel C.Notch signaling in development, tissue homeostasis, and disease..Physiol Rev2017;97:1235-94

[60] Harrison JS,Chang V.Oxygen saturation in the bone marrow of healthy volunteers..Blood2002;99:394

[61] Ke Q.Hypoxia-inducible factor-1 (HIF-1)..Mol Pharmacol2006;70:1469-80

[62] Sahlgren C,Jin S,Lendahl U.Notch signaling mediates hypoxia-induced tumor cell migration and invasion..Proc Natl Acad Sci USA2008;105:6392-7 PMCID:PMC2359811

[63] Zou J,Lu F,Dai J.Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells..J Hematol OncolJ Hematol Oncol2013;6:3 PMCID:PMC3544631

[64] Takebe N,Yang SX.Targeting notch signaling pathway in cancer: clinical development advances and challenges..Pharmacol Ther2014;141:140-9 PMCID:PMC3982918

[65] Takam Kamga P,Midolo M,Delfino P.Inhibition of notch signaling enhances chemosensitivity in B-cell precursor acute lymphoblastic leukemia..Cancer Res2019;79:639-49

[66] Nwabo Kamdje AH,Bifari F,Bassi G.Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow-derived mesenchymal stromal cells..Blood2011;118:380-9

[67] Meng X,Girodon F,Willman CL.GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia..Leukemia2011;25:1135-46 PMCID:PMC3170956

[68] DeAngelo DJ,Silverman LB,attar EC.A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias..Journal of Clinical Oncology2006;24:6585-6585

[69] Real PJ,Palomero T,Hernando E.Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia..Nat Med2009;15:50-8 PMCID:PMC2692090

[70] Balkwill F.TNF-alpha in promotion and progression of cancer..Cancer Metastasis Rev2006;25:409-16

[71] Riether C,Ochsenbein AF.Regulation of hematopoietic and leukemic stem cells by the immune system..Cell Death Differ2015;22:187-98 PMCID:PMC4291501

[72] Warzocha K,Ribeiro P,Dumontet C.Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin’s disease patients..Br J Cancer1998;77:2357-62 PMCID:PMC2150385

[73] Warzocha K,Bienvenu J,Charlot C.Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin’s lymphoma outcome..Blood1998;91:3574-81

[74] Lauten M,Stanulla M,Welte K.Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes..Leukemia2002;16:1437-42

[75] Gu L,Zhu N.Endogenous TNFalpha mediates cell survival and chemotherapy resistance by activating the PI3K/Akt pathway in acute lymphoblastic leukemia cells..Leukemia2006;20:900-4

[76] Lin JX.The common cytokine receptor γ chain family of cytokines..Cold Spring Harb Perspect Biol2018;10:a028449

[77] Zubiaga AM,Huber BT.IL-4 and IL-2 selectively rescue Th cell subsets from glucocorticoid-induced apoptosis..J Immunol Baltim Md1992;149:10712

[78] Kam JC,Surs W,Leung DY.Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids..J Immunol Baltim Md1993;151:3460-6

[79] Serafin V,Milani G,Pinazza M.Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia..Blood2017;130:2750-61

[80] McCarty JM,Deisher TA,Kaushansky K.Interleukin-4 induces endothelial vascular cell adhesion molecule-1 (VCAM-1) by an NF-kappa b-independent mechanism..FEBS Lett1995;372:194-8

[81] Juneja HS,Lee S.Vascular cell adhesion molecule-1 and VLA-4 are obligatory adhesion proteins in the heterotypic adherence between human leukemia/lymphoma cells and marrow stromal cells..Exp Hematol1993;21:444-50

[82] Mazzucchelli R.Interleukin-7 receptor expression: intelligent design..Nat Rev Immunol2007;7:144-54

[83] Ashwell JD,Vacchio MS.Cross-talk between the T cell antigen receptor and the glucocorticoid receptor regulates thymocyte development..Stem Cells Dayt Ohio1996;14:490-500

[84] Delgado-Martin C,Huang BJ,Zinter MS.JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias..Leukemia2017;31:2568 PMCID:PMC5729333

[85] Meyer LK,Roy R,Anica M.Glucocorticoids paradoxically induce intrinsic steroid resistance through a STAT5-mediated survival mechanism in T-cell acute lymphoblastic Leukemia..Blood2018;132:913

[86] Ray RJ,Williams DE.Characterization of thymic stromal-derived lymphopoietin (TSLP) in murine B cell development in vitro..Eur J Immunol1996;26:10-6

[87] Roberts KG,Zhang J,Zhao Y.Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia..Cancer Cell2012;22:153-66 PMCID:PMC3422513

[88] Harvey RC,Chen IM,Mikhail FM.Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, hispanic/latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia..Blood2010;115:5312-21 PMCID:PMC2902132

[89] Meyer LK,Maude SL,Hermiston ML.CRLF2 rearrangement status in ph-like all predicts intrinsic glucocorticoid resistance in vitro that is reversible with targeted MAPK and PI3K pathway inhibition..Blood2016;

[90] Cramer SD,Durum SK.Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment..Blood2016;128:473-8 PMCID:PMC4965903

[91] Maude SL,Delgado-Martin C,Robbins A.Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia..Blood2015;125:1759-67 PMCID:PMC4357583

[92] Maude SL,Vincent T,Sheen C.Targeting JAK1/2 and mTOR in murine xenograft models of ph-like acute lymphoblastic leukemia..Blood2012;120:3510-8 PMCID:PMC3482861

[93] Sokol CL.The chemokine system in innate immunity..Cold Spring Harb Perspect Biol2015; PMCID:PMC4448619

[94] Pozzobon T,Viola A.CXCR4 signaling in health and disease..Immunol Lett2016;177:6-15

[95] Gachet S,Passaro D,Alcalde H.Leukemia-initiating cell activity requires calcineurin in T-cell acute lymphoblastic leukemia..Leukemia2013;27:2289-300

[96] Passaro D,Catherinet C,Da Costa De Jesus C.CXCR4 is required for leukemia-initiating cell activity in T cell acute lymphoblastic leukemia..Cancer Cell2015;27:769-79

[97] van den Berk LCJ,Willemse ME,Luijendijk MW.Disturbed CXCR4/CXCL12 axis in paediatric precursor B-cell acute lymphoblastic leukaemia..Br J Haematol2014;166:240-9

[98] Konoplev S,Thomas DA,Burger J.Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia..Cancer2011;117:4689-95

[99] Sison EAR,McIntyre E,Small D.MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism..Br J Haematol2013;160:78597 PMCID:PMC4005340

[100] Sison EAR,Li L,Rau RE.Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition..Oncotarget2014;5:8947-58 PMCID:PMC4253409

[101] Cooper TM,Baker SD,Ahmed A.A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: a pediatric oncology experimental therapeutics investigators’ consortium study (POE 10-03)..Pediatr Blood Cancer2017;64:e26414 PMCID:PMC5675008

[102] Pieters R,Boos J,Silverman L.L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase..Cancer2011;117:238-49 PMCID:PMC3000881

[103] Kumar K,Walia S,Aggarwal D.L-asparaginase: an effective agent in the treatment of acute lymphoblastic leukemia..Leuk Lymphoma2014;55:256-62

[104] Iwamoto S,Downing JR,Campana D.Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase..J Clin Invest2007;117:1049-57 PMCID:PMC1821067